Goat Anti-Bag-1 (K-20) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
... at the 3, 3', 4, and 4' positions. It is intended...ation of Prostaglandin E2 (PGE2) by GC- or LC-mass...genase products of arachidonic acid and one of the...vity influences inflammation, fertility and partur...
Agarose Gel Loading Dye Mixture 6X (with ficoll) from GenScript Corporation
Site-directed Mutagenesis from Exon BioSystems
Biology Products:(Date:11/20/2009)...ass from the production of flax shives, and genera...ant related to those which engulf fields in spring... suggested by two studies carried out by Spanish a... Renewable and Sustainable Energy Reviews . , "Th...of view, the production of bioethanol from two, as...
(Date:11/19/2009)...ghly 15,000 years ago, at the end of the last ice ...als including such iconic creatures as mammoths, ... beavers began their precipitous slide to extinct...ing a land whose diversity of large animals equale...ains then or now, an entirely novel ecosystem emer...
(Date:11/19/2009)...ng Harbor, NY A four-year, multi-institutional ef... (CSHL) scientists culminated today in publication...ience revealing in unprecedented detail the DNA s...it is commonly called by North American consumers,...he most valuable agricultural crop grown in the Un...
Breaking Biology News(10 mins):Flax and yellow flowers can produce bioethanol 2After mastodons and mammoths, a transformed landscape 2After mastodons and mammoths, a transformed landscape 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 2Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 4Florida Hospital Cardiovascular Institute Completes House Wide Implementation of the LifeSync 28R 29 Wireless ECG System 47699 1Florida Hospital Cardiovascular Institute Completes House Wide Implementation of the LifeSync 28R 29 Wireless ECG System 47699 2Florida Hospital Cardiovascular Institute Completes House Wide Implementation of the LifeSync 28R 29 Wireless ECG System 47699 3Understand ARRA Spending Allocations with HIMSS Analytics 26amp 3B 238482 3B Market Intelligence 47698 1Understand ARRA Spending Allocations with HIMSS Analytics 26amp 3B 238482 3B Market Intelligence 47698 2Understand ARRA Spending Allocations with HIMSS Analytics 26amp 3B 238482 3B Market Intelligence 47698 3Dr Erika Says Newsweek 26apos 3Bs Attack on Oprah Ignores the Many Benefits of Her Health Care Advocacy 47696 1Dr Erika Says Newsweek 26apos 3Bs Attack on Oprah Ignores the Many Benefits of Her Health Care Advocacy 47696 2(Date:11/20/2009)...stCall/ -- Dendreon Corporation (Nasdaq: DNDN ) t...tration (FDA) provided written acknowledgement tha...ion (BLA) for PROVENGE® (sipuleucel-T) is a c...tion Drug User Fee Act (PDUFA) date of May 1, 2010...ded BLA. Dendreon is seeking licensure for PROVEN...
(Date:11/20/2009)...ently announced that Dr. Dominique Hebrault will p...Analytical Technology (PAT) in Green Chemistry and... (PRWEB) November 20, 2009 ...nology (PAT) in Green Chemistry and Green Engineer...hnology (PAT) case studies will be presented on ho...
(Date:11/19/2009)...9 Spherix Incorporated (... diabetes therapy, and a provider of technical and...t, biotechnology and pharmaceutical companies, ann...3 million registered direct placement to instituti...tock and warrants to purchase up to 1,104,348 addi...
(Date:11/19/2009)...Aegera Therapeutics Inc. announced today the dosin...udy of AEG35156, a targeted antisense therapeutic ...ications. ,, The study, entitled "An Open-Label...r of Apoptosis (XIAP) Antisense AEG35156 Given in ...in in AML Following Failure of a Single Standard D...
Breaking Biology Technology:Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2